An announcement from Theralase Technologies ( (TSE:TLT) ) is now available.
Theralase Technologies announced that its lead compound, Rutherrin, has shown efficacy in destroying Non-Hodgkin’s Lymphoma in an animal model when combined with Metformin and radiation. This development could potentially impact the company’s operations by enhancing its position in the oncology market, particularly in the treatment of Non-Hodgkin’s Lymphoma, which is a significant global health concern with a large market potential.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on the research and development of light, radiation, sound, and drug-activated small molecules. The company aims to create safe and effective treatments for various cancers, bacteria, and viruses.
YTD Price Performance: -10.91%
Average Trading Volume: 114,093
Technical Sentiment Consensus Rating: Hold
Current Market Cap: C$60.71M
Find detailed analytics on TLT stock on TipRanks’ Stock Analysis page.